Systemic Sclerosis (Scleroderma) Marketplace Analysed in GlobalData Report Available at MarketPublishers.com

25 Mar 2016 • by Natalie Aster

LONDON – A complex autoimmune disease affecting skin as well as multiple internal organs, systemic sclerosis (SSc) has a varied clinical presentation depending on a patient. Treatment of this disease is mainly aimed at managing complications of SSc within each internal organ, and no systemic or disease-modifying treatments are available.

Some new drugs are expected to emerge in the marketplace in the near term. Biologics are expected to hold the largest share of the SSc marketplace in 2024, and Actemra is expected to become a market leader.

Reimbursement frequently acts as a barrier to patients who receive a proper therapy as there is often a lack of evidence for the use of off-label therapies in the SSc.

Unmet needs are likely to remain in the upcoming years, since no disease-modifying or antifibrotic therapies are to be launched for SSc.

Insightful research report “Systemic Sclerosis (Scleroderma) - Opportunity Analysis and Forecast to 2024” drawn up by GlobalData offers comprehensive examination of the SSc marketplace. The study provides a detailed overview of this disease. It covers epidemiology and explores treatment options are available at present. The report assesses unmet needs and examines opportunities. The research study throws light on R&D strategies and comprises a pipeline assessment. It also includes a pipeline valuation analysis, historical data on this market as well as forecast figures.

Report Details:

OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) - Opportunity Analysis and Forecast to 2024
Published: December, 2015
Pages: 278
Price: US$ 9,495.00

Report Highlights:

• insightful overview of the disease;
• coverage of epidemiology;
• exploration of existing treatment options;
• deep insights into unmet needs;
• data on R&D activities;
• and more.

Other diseases investigated by GlobalData comprise:

• Acute Myeloid Leukemia
• Graft-Versus-Host Disease
• Gaucher Disease
• Opioid-Induced Constipation
• Fabry Disease 

More cutting-edge research studies by our market research partner can be found at GlobalData page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 
MarketPublishers.com